KWKathrin Weyer

Kathrin Weyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathrin Weyer has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Excessive protein uptake by endocytic receptors causes elevated proliferation and senescence in proximal tubules primarily in outer medulla of proteinuric mice

    by Yoshifumi Kurosaki, Fumitaka Kawakami, Akemi Imoto, Naokazu Sato, Motoshi Ouchi, Asuka Morita, Kathrin Weyer, Géraldine Mollet, Rei Kawashima, Yoshiko Iizuka, et al.

    Proteinuria contributes to the progression of chronic kidney disease and causes protein overload in proximal tubular epithelial cells (PTECs), fibrosis and inflammation. While protein overload is suggested to stimulate PTEC proliferation, its role in inducing cellular senescence remains unclear. This study investigated the effects of protein overload on PTEC proliferation and senescence using both in vivo and in vitro models. Experiments were performed using podocin-knockout (KO) (proteinuric model) and megalin-cubilin-podocin KO mice (proteinuric mice without endocytosis, triple KO). Human immortalized proximal tubular cells (RPTEC/TERT1) were incubated with human serum albumin (HSA) with and without fatty acids. Mouse kidneys and cells were analyzed by western blotting, quantitative RT-PCR, and immunofluorescence. In RPTEC/TERT1 cells, treatment with HSA carrying fatty acids induced proliferation and senescence. In vivo, proteinuric podocin-KO mice exhibited a significant increase in proliferation and senescence markers, particularly within the outer medulla. This response was markedly attenuated in triple-KO mice. Proliferation and senescence occurred in both receptor positive and negative cells. Analyses of cytokines, known to stimulate proliferation (PDGF-B) and senescence (TGFβ and MCP-1), were increased in podocin KO, but diminished in triple KO mice. Mechanistically, TGF-β receptor inhibition prevented HSA-induced senescence, whereas recombinant TGF-β sufficed to induce the phenotype in RPTEC/TERT1. In conclusion, excessive endocytosis of filtered proteins induces a changed cytokine environment with impact for PTEC proliferation and cellular senescence, particularly within the outer medulla.


  • Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria

    by Sandra Hummelgaard, Jean-Claude Kresse, Michael Schou Jensen, Simon Glerup, Kathrin Weyer

    Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD). Key features of CKD include proteinuria and reduced glomerular filtration rate, both of which are linked to disease progression and adverse outcomes. Dyslipidemia, a major CVD risk factor, often correlates with CKD severity and is inadequately addressed by conventional therapies. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in lipid metabolism by modulating low-density lipoprotein receptor (LDLR) levels and has emerged as a therapeutic target for managing dyslipidemia. PCSK9 inhibitors, including monoclonal antibodies and siRNA, effectively lower LDL cholesterol levels and have demonstrated safety in patients with mild to moderate CKD. Recent findings indicate that PCSK9 aggravates proteinuria by interacting with and downregulating megalin, a proximal tubule receptor essential for protein reabsorption in the kidney. Inhibition of PCSK9 has been shown to preserve megalin levels, reduce proteinuria, and improve the disease phenotype in experimental models. However, conflicting data from preclinical studies underscore the need for further research to clarify the mechanisms underlying PCSK9's role in kidney disease. This review highlights the potential of PCSK9 inhibition in addressing proteinuria and dyslipidemia in CKD, emphasizing its promise as a therapeutic strategy, while addressing current challenges and future directions for research.


  • Open Access

    Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 rats

    by Sandra Hummelgaard, Henning Hvid, Henrik Birn, Simon Glerup, Nikola Tom, Mesut Bilgin, Jeppe Egedal Kirchhoff, Kathrin Weyer

    New treatments to slow kidney disease progression and reduce cardiovascular disease risk are needed for chronic kidney disease (CKD). We investigated the cholesterol-lowering PCSK9 inhibitor alirocumab as a new treatment for proteinuric CKD and the effect of SGLT2 inhibition using empagliflozin in obese ZSF1 rats. Regarding renoprotection, our findings were contradictory with previous preclinical studies and clinical data, suggesting that different pathophysiological mechanisms may apply to this rat model.


  • Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria

    by Gustaf L. Isaksson, Gitte R. Hinrichs, Henrik Andersen, Marie L. Bach, Kathrin Weyer, Rikke Zachar, Jan Erik Henriksen, Kirsten Madsen, Ida K. Lund, Géraldine Mollet, et al.

    Significance Statement: Proteinuria predicts accelerated decline in kidney function in CKD. The pathologic mechanisms are not well known, but aberrantly filtered proteins with enzymatic activity might be involved. The urokinase-type plasminogen activator (uPA)-plasminogen cascade activates complement and generates C3a and C5a in vitro/ex vivo in urine from healthy persons when exogenous, inactive, plasminogen, and complement factors are added. Amiloride inhibits uPA and attenuates complement activation in vitro and in vivo. In conditional podocin knockout (KO) mice with severe proteinuria, blocking of uPA with monoclonal antibodies significantly reduces the urine excretion of C3a and C5a and lowers tissue NLRP3-inflammasome protein without major changes in early fibrosis markers. This mechanism provides a link to proinflammatory signaling in proteinuria with possible long-term consequences for kidney function. Background: Persistent proteinuria is associated with tubular interstitial inflammation and predicts progressive kidney injury. In proteinuria, plasminogen is aberrantly filtered and activated by urokinase-type plasminogen activator (uPA), which promotes kidney fibrosis. We hypothesized that plasmin activates filtered complement factors C3 and C5 directly in tubular fluid, generating anaphylatoxins, and that this is attenuated by amiloride, an off-target uPA inhibitor. Methods: Purified C3, C5, plasminogen, urokinase, and urine from healthy humans were used for in vitro/ex vivo studies. Complement activation was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblotting, and ELISA. Urine and plasma from patients with diabetic nephropathy treated with high-dose amiloride and from mice with proteinuria (podocin knockout [KO]) treated with amiloride or inhibitory anti-uPA antibodies were analyzed. Results: The combination of uPA and plasminogen generated anaphylatoxins C3a and C5a from intact C3 and C5 and was inhibited by amiloride. Addition of exogenous plasminogen was sufficient for urine from healthy humans to activate complement. Conditional podocin KO in mice led to severe proteinuria and C3a and C5a urine excretion, which was attenuated reversibly by amiloride treatment for 4 days and reduced by >50% by inhibitory anti-uPA antibodies without altering proteinuria. NOD-, LRR- and pyrin domain-containing protein 3-inflammasome protein was reduced with no concomitant effect on fibrosis. In patients with diabetic nephropathy, amiloride reduced urinary excretion of C3dg and sC5b-9 significantly. Conclusions: In conditions with proteinuria, uPA-plasmin generates anaphylatoxins in tubular fluid and promotes downstream complement activation sensitive to amiloride. This mechanism links proteinuria to intratubular proinflammatory signaling. In perspective, amiloride could exert reno-protective effects beyond natriuresis and BP reduction. Clinical Trial registry name and registration number: Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease, NCT01918488 and Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients, NCT03036748.


  • Open Access

    Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome

    by Cecilie K. Skeby, Sandra Hummelgaard, Camilla Gustafsen, Federica Petrillo, Kathrine P. Frederiksen, Ditte Olsen, Tilde Kristensen, Per Ivarsen, Peder Madsen, Erik I. Christensen, et al.


  • Top Cited Papers
    Open Access

    Targeting PCSK9 to tackle cardiovascular disease

    by Sandra Hummelgaard, Joachim Pold Vilstrup, Camilla Gustafsen, Simon Glerup, Kathrin Weyer


  • Megalin-Mediated Endocytosis in the Kidney Proximal Tubule: Relevance to Regulation of the Renal Renin-Angiotensin System

    by Sandra Hummelgaard, Kathrin Weyer

    The kidney proximal tubule is a major target tissue of the renin-angiotensin system (RAS). Megalin is an endocytic multiligand receptor abundantly expressed in the proximal tubule where it drives reabsorption of peptides and proteins from the glomerular ultrafiltrate. All major RAS components are present in the kidney proximal tubules. Here, megalin drives endocytosis of angiotensinogen (AGT), prorenin, and renin, while angiotensin-converting enzyme is localised at the brush border of the proximal tubule cells. Intrarenal formation of the key RAS effector angiotensin II (ANG II) occurs, and liver-derived AGT appears to be the primary source. New studies further suggest that megalin-mediated reabsorption of liver-derived AGT contributes to renal ANG II levels and thereby may influence renal RAS activity. This mini-review presents the recent advances on RAS in the proximal tubule and the involvement of megalin in the uptake and regulation of local RAS and discusses the possibility that megalin is involved in blood pressure regulation.


  • Open Access

    Extrafollicular responses are sufficient to drive initiation of autoimmunity and early disease hallmarks of lupus

    by Lasse F. Voss, Amanda J. Howarth, Thomas R. Wittenborn, Sandra Hummelgaard, Kristian Juul-Madsen, Kristian S. Kastberg, Mathias K. Pedersen, Lisbeth Jensen, Anastasios D. Papanastasiou, Thomas Vorup-Jensen, et al.

    Many autoimmune diseases are characterized by germinal center (GC) derived affinity-matured, class-switched autoantibodies. Strategies to block GC formation and progression are currently being explored clinically, however, extrafollicular responses may also contribute to early events in autoimmunity. To investigate the relative contribution of these two pathways in autoimmune disease development, we leveraged a transgenic strategy to genetically block the GC pathway. Surprisingly, this accelerated extrafollicular responses and failed to curb autoimmune progression in two lupus models. In vitro , loss of the GC transcription factor Bcl-6 prevented cellular expansion and accelerated plasma cell differentiation, suggesting the in vivo phenotype was caused by rewiring of B cell intrinsic transcriptional programming. In a competitive scenario in vivo , B cells harboring the genetic GC block contributed disproportionately to the plasma cell output. Taken together, this emphasizes the extrafollicular pathway as a key contributor to autoimmune progression, and suggests that strategies aimed at blocking GCs should simultaneously target this pathway to avoid rerouting the pathogenic response. Highlights: - A genetic GC block fails to prevent autoimmune progression in two lupus models - An intrinsic GC block drives B cell differentiation into terminally differentiated plasma cells in vitro - B cells harboring a GC block competitively contribute to the plasma cell compartment in an autoreactive setting in vivo - Lupus mice with a GC block display immune complex deposition in kidney glomeruli that is indistinguishable from their wild-type counterparts Summary: Affinity-matured autoantibodies generated in germinal centers are a hallmark of autoimmune diseases. Voss et al. block germinal centers in two autoimmune models, but surprisingly find that disease progresses unimpeded. They identify the extrafollicular pathway as a ‘backdoor to autoimmunity’.


  • Distinct functions of megalin and cubilin receptors in recovery of normal and nephrotic levels of filtered albumin

    by Qidong Ren, Kathrin Weyer, Youssef Rbaibi, Kimberly R. Long, Roderick J. Tan, Rikke Nielsen, Erik I. Christensen, Catherine J. Baty, Ossama B. Kashlan, Ora A. Weisz

    Proximal tubule (PT) cells express a single saturable albumin-binding site whose affinity matches the estimated tubular concentration of albumin; however, albumin uptake capacity is greatly increased under nephrotic conditions. Deciphering the individual contributions of megalin and cubilin to the uptake of normal and nephrotic levels of albumin is impossible in vivo, as knockout of megalin in mice globally disrupts PT endocytic uptake. We quantified concentration-dependent albumin uptake in an optimized opossum kidney cell culture model and fit the kinetic profiles to identify albumin-binding affinities and uptake capacities. Mathematical deconvolution fit best to a three-component model that included saturable high- and low-affinity uptake sites for albumin and underlying nonsaturable uptake consistent with passive uptake of albumin in the fluid phase. Knockdown of cubilin or its chaperone amnionless selectively reduced the binding capacity of the high-affinity site, whereas knockdown of megalin impacted the low-affinity site. Knockdown of disabled-2 decreased the capacities of both binding sites. Additionally, knockdown of megalin or disabled-2 profoundly inhibited the uptake of a fluid phase marker, with cubilin knockdown having a more modest effect. We propose a novel model for albumin retrieval along the PT in which cubilin and megalin receptors have different functions in recovering filtered albumin in proximal tubule cells. Cubilin binding to albumin is tuned to capture normally filtered levels of the protein. In contrast, megalin binding to albumin is of lower affinity, and its expression is also essential for enabling the recovery of high concentrations of albumin in the fluid phase.